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Abstract
Setting—KwaZulu-Natal, South Africa a predominantly rural province with high burdens of TB, 
MDR-TB and HIV infection.
Objective—To determine the most effective model of care by comparing MDR-TB treatment 
outcomes at community-based sites with traditional care at a central, specialised hospital.
Design—A non-randomised observational prospective cohort study comparing community-based 
and centralised care. Patients at community-based sites were closer to home, had easier access to 
care and home-based care was available from treatment initiation.
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Results—Four community-based sites treated 736 patients, while 813 were treated at the 
centralised hospital (a total of 1549 patients). Overall, 75% were HIV co-infected (community: 
76% vs. hospitalised: 73%, p=0.45) and 86% received antiretroviral therapy (community: 91% vs. 
hospitalised: 82%, p=0.22).
In multivariate analysis MDR-TB patients were more likely to have a successful treatment 
outcome if they were treated at a community-based site (adjusted OR=1.43, p=0.01). However, 
there was heterogeneity in outcomes at the four community-based sites, with Site 1 demonstrating 
that home-based care was associated with increased treatment success of 72% compared with 
success of between 52 - 60% at the other three sites.
Conclusion—Community-based care for patients with MDR-TB was more effective than care in 
a central, specialised hospital. Home-based care further increased treatment success.
Keywords
Models of care; HIV; outcomes
BACKGROUND
Multidrug-resistant tuberculosis (MDR-TB), defined as TB resistant to isoniazid and 
rifampicin, is a critical threat to global TB control and is associated with high mortality in 
settings with HIV co-infection.1,2 MDR-TB treatment is more difficult for patients to 
tolerate than first-line TB therapy, due to the long duration of treatment (18–24 months), 
frequent medication toxicities, and daily administration of an injectable drug for at least six 
months. Consequently, most countries have adopted inpatient models of care at centralised, 
specialised hospitals.
South Africa has one of the largest drug-resistant TB epidemics in the world.1 KwaZulu-
Natal Province has emerged as a global hotspot of the TB, drug-resistant TB, and HIV 
syndemic, with 76% of MDR-TB patients co-infected with HIV, and MDR-TB mortality 
rates of 71%.3-5 Local management of MDR-TB was based on hospitalisation in a 
centralised specialised hospital for the initial six months of treatment, to facilitate daily 
injections and allow close monitoring of adverse events and adherence. Following discharge, 
and for the remaining period of treatment (18 months or longer), patients were expected to 
return for monthly out-patient visits, which for some patients entailed travelling 500kms to 
reach the hospital. In this setting, the escalating burden of MDR-TB together with limited 
bed capacity resulted in long waiting lists, an average delay of 111 days for hospital 
admission and treatment initiation3 and in 2007, only 32% of MDR-TB patients accessed 
treatment.6 Furthermore, patients were discharged before the end of the injectable phase of 
treatment to facilities unfamiliar with MDR-TB treatment, resulting in poor treatment 
outcomes and high default rates. 3-5
An alternate community-based model of care could increase MDR-TB treatment capacity 
(currently limited by hospital bed availability), and make treatment more accessible by being 
available closer to patient’s homes, enhancing support to patients and their families. Lengthy 
arduous trips to receive health care could be limited, thus reducing patient default and 
improving treatment outcomes. Furthermore, shorter periods of hospitalisation would make 
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it possible to treat more patients and reduce the time to treatment initiation. Alternate models 
of care have been implemented in small study samples in other countries7-11 and in other 
southern African settings.12 However, to our knowledge, no study has compared treatment 
outcomes in a community with a centralised setting. And, little is known about the potential 
viability and ease of implementation of these alternate models of care on a large scale by a 
public health service, particularly in areas bruised by TB and HIV epidemics.
In 2008, the KwaZulu-Natal provincial Department of Health began piloting community-
based care at four sites. This study was designed to evaluate the community-based model of 
MDR-TB care at these sites, based on relative treatment success for MDR-TB patients with 
and without HIV co-infection, in comparison with care in a centralised setting. Here we 
report final treatment outcomes and predictors for patients treated in community-based 
versus centralised care.
METHODS
Study design, patients and procedures
This prospective cohort study was conducted in the province of KwaZulu-Natal, South 
Africa. Between 1 July 2008 and 30 June 2010, 1549 patients aged ?18 years with a 
laboratory confirmed diagnosis of MDR-TB were enrolled (Figure 1). Patients were 
excluded if they were resistant to a single first-line TB drug (rifampicin, isoniazid, 
pyrazinamide or ethambutol), or were resistant to isoniazid and rifampicin with any second-
line TB drugs. Patients who received care at both a community-based site and the centralised 
hospital, or who were participating in an MDR-TB clinical trial were also excluded. All 
patients who lived within the catchment area of each community-based site were enrolled at 
that site if they met the study criteria. At the centralised hospital all patients who met the 
study criteria were enrolled, unless they came from the catchment areas of the community-
based sites.
Intervention
Patients diagnosed with MDR-TB were referred to either a community-based site or the 
centralised hospital for initiation of MDR-TB therapy, depending on where they lived. All 
patients received standardized MDR anti-tuberculosis therapy and ART in accordance with 
national guidelines.13,14 During the initial intensive phase of treatment (usually 4-6 months), 
patients were started on a regimen of kanamycin (Km), pyrazinamide (Z), ethambutol (E), 
ethionamide (Eto), ofloxacin (Ofx), and cycloserine (Cs). This was followed by a 
continuation phase of at least 18 months of oral treatment (Z, E, Eto, Ofx and Cs).
The four community-based sites were attached to purposively selected rural hospitals in 
areas where large numbers of MDR-TB patients were being diagnosed. Non-specialist 
doctors provided care to MDR-TB patients at these sites, referring patients requiring 
specialist care to the centralised hospital. Once discharged, all patients attended monthly 
follow-up treatment monitoring visits at the community-based sites. Home-based care was 
available for patients discharged from the community-based sites during the intensive phase 
of treatment, with kanamycin injections administered daily either at a local clinic or by 
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mobile injection teams that visited patients in their homes. Mobile injection teams also 
followed up patients who had defaulted. The guiding principles and detailed implementation 
of this model have been reported previously.15,16 The implementation of injection teams 
varied across the sites. At Site 1, 16 injection teams were mobilised in the first year of the 
programme (2008). Site 2 mobilised two teams in 2009; Site 3, two teams towards the end 
of 2011; and Site 4 none at all. Direct-observation of therapy (DOT) is included in the 
national TB and MDR-TB guidelines, but is seldom implemented; most patients self-
administered oral treatment and adherence was seldom monitored.
At the community-based sites, home-based care from the time of treatment initiation was 
available, but for a number of reasons most patients (95%) were initially hospitalised: (1) 
many patients co-infected with MDR-TB and HIV were very ill at the time of MDR-TB 
diagnosis, requiring hospitalisation; (2) clinicians unfamiliar with the co-management of 
MDR-TB and HIV wanted to monitor patients closely; (3) the extent of implementation of 
home-based care varied across the community-based sites; (4) home circumstances assessed 
by a social worker were determined to be unsupportive of adherence. The median duration 
of hospitalisation was similar at the community-based sites and centralised hospital (143 
versus 144 days), but varied across the four community-based sites from 96 days at Site 1, to 
180 days at Site 3 (Table 3).
End points
The primary outcome variables were treatment outcome as defined by WHO in 2008 (Table 
1),17,18 and survival time over course of treatment (2008 definitions were used as most 
treatment outcomes had been assigned by the time the 2011 revised definitions were 
published). Treatment initiation delay, a secondary outcome, was defined as the interval 
between initial sputum collection and treatment start.
Statistical analysis
We reviewed medical records to collect patient-related demographic, clinical, 
pharmaceutical and laboratory data. Patients’ response to treatment was monitored via 
continuous data collection from medical records and the laboratory database for the duration 
of treatment. Data collection was complete by October 2012. Baseline characteristics and 
treatment outcomes were described using simple frequencies. Medians among the individual 
community-based sites were compared using the Kruskal-Wallis non-parametric test. 
General linear models (GLM) using the binomial or normal distribution were used to 
compare proportions and/or means respectively between sites; also to compare medians 
using rank values. Logistic regression was utilized to assess the effect of risk factors on 
successful vs. unsuccessful outcomes. All models utilized the GEE (generalised estimating 
equation) procedure to adjust for clustering from the multiple hospitals comprising the 
community-based sites. The Cox proportional hazards model, incorporating a robust 
“sandwich” variance estimate to allow for clustering of patients from the same site, was used 
to assess the effect of certain risk factors on time to death. Patients who did not experience 
the event measured were considered censored at date of final outcome. All multivariate 
models used a univariate threshold of p<0.25 in order for variables to be considered for 
inclusion. Analyses were conducted using SAS V9.2 (SAS Institute, Cary, NC, USA).
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The study protocol was approved by the Biomedical Research Ethics Committee at the 
University of KwaZulu-Natal (Ref: BF052/09).
RESULTS
Of the 1549 patients prospectively enrolled in the study, 736 were treated at the community-
based sites and 813 at the centralised hospital (Figure 1). Ninety-four percent of all patients 
were tested for HIV, and co-infection rates were high at both the community-based sites and 
centralised hospital (76.3% vs. 73.1%), with 91.3% of patients at the community-based sites 
receiving ART compared with 82% at the centralised hospital (Table 2). Patients at the 
community-based sites were less likely to have a history of TB (55.8% vs. 95.7%, p<0.001), 
and had a lower median pre-treatment weight (50 vs. 53 kg, p <0.001). More patients at the 
community-based sites were smear-positive at diagnosis (75.7% vs. 60.4%, p<0.001).
At the community-based sites significantly more patients were cured (50.7% vs. 34.4%, 
p<0.001), and significantly fewer patients defaulted (14.5% vs. 28.3%, p=0.004) (Table 3). 
In addition, more patients achieved a successful treatment outcome (58%) than at the 
centralised hospital (54%). In multivariate analysis adjusting for HIV status, age, previous 
MDR-TB infection, and pre-treatment weight, patients were more likely to have a successful 
treatment outcome if they were treated at a community-based site (adjusted OR=1.43, 
p=0.01) (Table 4). There was no effect modification on MDR-TB outcomes of HIV status 
and ART. Regardless of site, HIV-positive patients were at greater risk of dying (16.3% vs. 
11.4%, p=0.022) (Table 5).
Survival probability appeared slightly worse at the community-based sites (p=0.064), with 
higher mortality at Site 4 influencing overall mortality (Table 3). Multivariate analysis 
showed significantly increased mortality for patients who were older than 30 (HR=1.64, 
p=0.010); had low pre-treatment weight (HR=1.42, p=0.041); were HIV-positive and not on 
ART (HR=1.77, p=0.018, referent HIV-negative) (Table 4).
There was heterogeneity in treatment outcomes across the four community-based sites with 
treatment success varying from 72% (Site 1) to 51.7% (Site 4) (p<0.01). Seventy patients 
(10%) at the community-based sites received exclusive home-based care. There was no 
difference in successful treatment outcomes in these patients compared with those who were 
initially hospitalised at the community-based sites (59% vs. 61%, p=0.511).
Treatment initiation delay was shorter at the community-based sites than the centralised 
hospital (median=72 vs. 92 days respectively, p<0.001) (Table 3) - but delay was not 
associated with treatment outcomes or mortality.
DISCUSSION
Our study shows that community-based care is more effective than centralised care as 
evidenced by higher cure (50.7% vs. 34.3%, p<0.001), lower default (14.5% vs. 28.3%, 
p=0.004) and earlier treatment initiation (72 vs. 92 days, p<0.001). Confirmatory logistic 
regression models adjusted for HIV status and receipt of ART, showed that patients at 
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community-based sites were more likely to have a successful treatment outcome (adjusted 
OR=1.43, p=0.01) (Table 4).
WHO, together with others, is now promoting ambulatory models of care for MDR-TB 
patients.19-21 Our study findings support these calls as the introduction of community-based 
care increased the capacity of the public health system to provide treatment to approximately 
900 more MDR-TB patients.22 Furthermore, higher successful treatment outcomes and 
lower default rates at community-based sites suggest that community-based care may 
address patients’ needs more successfully as care closer to home is easier to access, 
convenient, allows family support and eliminates long and costly trips to a centralised 
hospital.
Other studies reporting outcomes for community-based MDR-TB care have documented 
similar success rates, but have involved small numbers of patients and been implemented 
with support of an external organisation.7,8,12 In contrast, our study reports findings of a 
programme implemented and funded entirely by the Department of Health. This increases 
the generalizability of our findings to other resource-limited situations.
There was considerable heterogeneity in treatment outcomes across the four community-
based sites as treatment success varied from a high of 72% at Site 1 to a low of 51.7% at Site 
4 (p<0.002). Higher treatment success at Site 1 was as a consequence of it being in a well-
functioning and supportive district, where district leadership took ownership of the MDR-
TB problem, re-organised and re-aligned health service components and allocated sufficient 
financial resources. This translated into the provision of 16 injection teams, additional staff 
at the outpatients’ clinic who established systems, implementation of a locally developed 
patient treatment literacy programme and home-assessment by a multi-disciplinary team 
prior to patient discharge. These programme components were partially implemented at 
other decentralised sites. However, even when removing Site 1 from the analysis, treatment 
at the community-based sites remained as effective as treatment in the centralised site. 
Although the heterogeneity in treatment success across the community-based sites was 
greater than expected, we believe this adequately reflects variation in health service 
provision across different sites when services are expanded or a new programme is 
introduced. The variation in the number of days of hospitalisation at the decentralised sites 
(Site 1= 96; Site 3= 180; p<0.002) illustrates the different interpretation and implementation 
of guidelines, highlighting the importance of regular monitoring and support during service 
expansion, to ensure health systems are functional and new programmes implemented in 
accordance with guidelines, thereby optimising the probability of treatment success.23-25
Survival rates at the community-based sites were somewhat lower than at the centralised site 
(Table 3). There are five possible explanations. Firstly, survival bias may play a role at the 
centralised hospital where the median treatment initiation delay was longer than at the 
community-based sites (92 vs. 72 days). Secondly, experienced clinicians at the centralised 
hospital with access to more sophisticated laboratory and other investigations were able to 
detect patients failing to respond to treatment more quickly. Thirdly, there were a number of 
patients from the centralised hospital whose treatment outcomes were not known as their 
clinical records were missing. Although we are confident that no patient with a successful 
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outcome was incorrectly classified, we may have misclassified patients as defaulters when in 
fact they had died, thus underestimating mortality at the centralised hospital. A number of 
studies evaluating ART programmes, particularly those with large proportions of TB co-
infection, have documented high mortality in patients lost to follow up.26,27 Fourthly, 
baseline characteristics of patients at the community-based sites differed from those at the 
centralised hospital, suggesting that this patient population was more physically 
impoverished. Fifthly, there was considerable heterogeneity in mortality across the 
decentralised sites. The mortality rate at Site 4 was twice that at Site 1, influencing overall 
mortality.
Survival improved for the duration of the study. Across all sites, MDR-TB patients starting 
treatment in 2008 and 2009 were – respectively – 1.77 and 1.53 times more likely to die than 
patients starting treatment in 2010 (Table 4). Possible reasons for this improvement include 
policy changes in 2009 which promoted earlier initiation of ART for patients with MDR-TB 
and HIV,28 new drugs introduced into the MDR-TB regimen, and improvement of patient 
management at the community-based sites with time and experience.
This operational study evaluated an intervention implemented by the public sector and we 
therefore had limited control over the design, scope and quality of implementation. Data 
used for programme evaluation were routinely collected by health workers, and were 
occasionally incomplete. Furthermore, during the study, as clinical records for some patients 
at the centralised site could not be found, we took several steps to determine the treatment 
outcomes of these patients. These included searching the national laboratory database 
(which demonstrated on-going care) and consulting the national registration system to verify 
if the patient had died. At the end of the analysis all patients had been assigned an outcome.
CONCLUSION
We conclude that community-based care is more effective than care in a centralised setting, 
based on similar treatment success rate, lower defaulter rate and shorter time to treatment 
initiation at the four community-based sites. Even in the presence of HIV co-infection, 
community-based care increased treatment success. Still to be determined is whether 
exclusive home-based care can achieve the same treatment success.
As alternate models of care for patients are introduced or expanded, we recommend regular 
monitoring and support of district and facility managers and individual health workers to 
ensure that services are equitable, guidelines adhered to, quality of care is optimal and the 
chance of treatment success optimised.
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Cure was defined as completion of treatment and >5 consecutive negative culture results in the final 12 months
of treatment. A patient was still considered cured If only one positive culture was reported during this time, was
clinically well, and this positive culture was followed by at least 3 consecutive negative cultures taken at least 30
days apart.
Treatment
completion Treatment completion referred to completion of therapy but without bacteriologic documentation of cure.
Treatment success
Treatment success has been defined as the percentage of patients in whom the treatment outcome was either
cured or completed. That is, “% successful = no. of patients cured + no. of patients completed treatment /Total
no. initiated treatment × 100”.
Treatment failure
Treatment failure was defined as having more than one positive culture in the final 12 months of therapy, or if
any one of the final three cultures was positive, or if more than one drug in the treatment regimen was replaced,
or if treatment was terminated due to adverse events or no clinical improvement.
Default Default was defined as an interruption in treatment for ≥ 2 consecutive months for any reason.
Death Death was defined as all-cause mortality during MDR-TB treatment.
Unsuccessful
treatment
Unsuccessful treatment outcome has been defined as the percentage of patients in whom the treatment
outcome was died, defaulted, or failed treatment.
Transferred out A patient with MDR-TB who was transferred to another reporting and recording unit a year after study-enrolment whose treatment outcome is unknown.
*
Treatment outcome definitions used are 2008 WHO definitions for the management of MDR-TB.17,18
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Site 1 Site 2 Site 3 Site 4 p-value
n=813 n=736 n=125 n=148 n=202 n=261
Female 413 (50.8) 390 (52.9) 68 (54.4) 88 (59.5) 98 (48.5) 136 (52.1) 0.2330.230
Median age (years, 




Previous TB 778 (95.7) 411 (55.8) 87 (69.6) 81 (54.7) 136 (67.3) 107 (41.0) <0.001<0.001




491 (60.4) 557 (75.7) 75 (60.0) 121 (81.8) 152 (75.3) 209 (80.1) <0.001<0.001
Resistant to ≥3 
drugs at
diagnosis
467 (57.4) 410 (55.7) 74 (59.2) 91 (61.5) 101 (50.0) 144 (55.2) 0.3640.149
Initial regimen ≥6 





n/total tested (%) 576/788 (73.1) 528/692 (76.3) 96/124 (77.4) 112/144 (77.8) 123/189 (65.1) 197/235 (83.8)
0.450
<0.001




282 345 82 72 92 99
Median baseline 
CD4


















454/554 (82.0) 440/482 (91.3) 92/94 (97.9) 103/106 (97.2) 116/117 (99.2) 129/165 (78.2) 0.225<0.001
Data are number (%), unless otherwise indicated
MDR-TB = multidrug-resistant tuberculosis
IQR = interquartile range
HIV = human immunodeficiency virus
ART = antiretroviral therapy
*
On ART at start of MDR-TB therapy or within two weeks of MDR-TB treatment initiation. Denominator excludes HIV+ patients with missing 
ART information.
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Table 3






Site 1 Site 2 Site 3 Site 4 p-value
n=813 n=736 n=125 n=148 n=202 n=261
Treatment outcomes
¶




¥ 159 (19.6) 54 (7.3) 12 (9.6) 8 (5.4) 19 (9.4) 15 (5.8) <0.0010.265
 Treatment success** 439 (54.0) 427 (58.0) 90 (72.0) 89 (60.1) 113 (55.9) 135 (51.7)
0.180
0.002
Died‡ 113 (13.9) 133 (18.1) 17 (13.6) 22 (14.9) 25 (12.4) 69 (26.4)
0.211
<0.001
Failed^ 29 (3.6) 49 (6.7) 7 (5.6) 11 (7.4) 12 (5.9) 19 (7.3)
<0.001
0.872
Default‡‡ 230 (28.3) 107 (14.5) 9 (7.2) 20 (13.5) 50 (24.8) 28 (10.7)
0.004
<0.001
Transferred out^^ 2 (0.25) 20 (2.7) 2 (1.6) 6 (4.1) 2 (1.0) 10 (3.8)
<0.001
0.130
Clinical course of 
treatment
n









































Median duration of 
MDR-
TB treatment (days), 
(IQR)




positive at treatment 
start
(%)
511/638 (80) 536/672 (80) 95/111 (86) 118/139 (85) 140/174 (81) 183/248 (74) 0.9830.017
n


















Median no of days 
follow up

















Data are number (%), unless otherwise indicated
¶
Treatment outcome definitions used are WHO definitions for the management of MDR-TB (Box 1). 17,18
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*
Cured: Cure was defined as completion of treatment and >5 consecutive negative culture results in the final 12 months of treatment. A patient 
was still considered cured If only one positive culture was reported during this time, was clinically well, and this positive culture was followed by 
at least 3 consecutive negative cultures taken at least 30 days apart.
¥
Treatment completed: Treatment completion referred to completion of therapy but without bacteriologic documentation of cure.
**
Treatment success: Treatment success has been defined as the percentage of patients in whom the treatment outcome was either cured or 
completed. That is, “% successful = no. of patients cured + no. of patients completed treatment /Total no. initiated treatment × 100”.has been 
defined as the percentage of patients in whom the treatment outcome was either cured or completed. That is, “% successful = no. of patients cured 
+ no. of patients completed Rx/Total no. initiated Rx × 100.
‡
Died: Death was defined as all-cause mortality during MDR-TB treatment.
^
Failed: Treatment failure was defined as having more than one positive culture in the final 12 months of therapy, or if any one of the final three 
cultures was positive, or if more than one drug in the treatment regimen was replaced, or if treatment was terminated due to adverse events or no 
clinical improvement.
‡‡
Default: Default was defined as an interruption in treatment for > 2 consecutive months for any reason.
^^
Transferred out: A patient with MDR-TB who was transferred to another reporting and recording unit a year after study-enrolment whose 
treatment outcome is unknown.
¶¶
This definition is an adaptation of the WHO definition, as date of DST results was not routinely recorded.29
‡‡
Culture conversion was defined as the interval between the treatment start date and the first of two consecutive negative sputum cultures taken at 
least one month apart.17
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Table 4
Predictors of treatment success and death in patients with MDR-TB from the community-based sites and 
centralised hospital in KwaZulu-Natal, South Africa
Predictors of treatment success





Community-based site 1.19 (0.91 to 1.57) 0.207 1.43 (1.09 to 1.88) 0.010
Female gender 1.21 (1.09 to 1.36) <0.001 1.19 (1.05 to 1.34) 0.007
Age≥30 years 1.28 (1.01 1.63) 0.042 1.40 (1.18 to 1.65) <0.001
No previous MDR-TB 2.63 (2.05 to 3.39) <0.001 2.51 (1.64 to 3.84) <0.001
HIV and ART status
 HIV positive, on ART
 HIV negative
 HIV positive, not on ART
1.63 (1.40 to 1.89)
1.43 (1.08 to 1.90)
Reference
<0.001 0.012
1.5 (1.38 to 1.62)
1.35 (1.05 to 1.75)
Reference
<0.001 0.021
Weight, ≥50 kg female or ≥55 kg male 1.31 (1.06 to 1.63) 0.013 1.28 (1.06 to 1.56) 0.011
Length of hospitalization^ 1.01 (0.99 to 1.01) 0.091 **
Culture conversion <90 days from Rx
start¶
1.71 (1.44 to 2.03) <0.001 **
Predictors of death
Variables UnadjustedHazards Ratio (95%) CI) p-value
Multivariate Hazards
Ratio (95% CI) p-value
Community-based Site 1.27 (0.82 to 1.96) 0.289 1.06 (0.87 to1.30) 0.567
Age, ≥30 years 1.70 (1.03 to 2.83) 0.039 1.61 (1.09 to 2.38) 0.018
Low pre-treatment weight,
≤50 kg female or≤55 kg male 1.35 (0.88 to 2.05) 0.161 1.40 (1.00 to 1.96) 0.048





1.78 (1.35 to 2.35)
1.27 (1.09 to 1.48)
Reference
<.001  .002
1.77 (1.36 to 2.31)
1.53 (1.05 to 2.22)
Reference
<0.001  0.027
HIV and ART status
 HIV positive, not on ART
 HIV positive, on ART
 HIV negative
2.12 (1.54 to 2.93)




1.59 (0.98 to 2.59)




Median baseline CD4 count




1.90 (1.11 to 3.26)




Length of hospitalization^ 0.92 (0.88 to 0.96) <0.001 **
Extensive chest disease‡ 2.54 (1.00 to 6.44) 0.049 **
HIV = human immunodeficiency virus
ART = antiretroviral therapy
^
For every additional 14 day stay
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¶
culture conversion <90 days defined as two consecutive negative sputum cultures taken at least 1 month apart less than 90 days after treatment 
started.
**
Not included in multivariate model because too few non-missing values.
‡
Extensive chest disease defined if bilateral involvement or cavities present on chest X-ray.
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Table 5
Treatment outcomes stratified by HIV status in patients with MDR-TB in KwaZulu-Natal, South Africa¶










n=576 n=528 n=212 n=164
Cured* 200 (34.7) 286 (54.2) <0.001 71 (33.5) 79 (48.2) <0.001
Treatment
completed¥
109 (18.9) 35 (6.6) <0.001 46 (21.7) 16 (9.8) <0.001
Treatment
success**
309 (53.6) 321 (60.8) 0.013 117 (55.2) 95 (57.9) 0.372
Died† 82 (14.2) 98 (18.6) 0.114 24 (11.3) 19 (11.6) 0.970
Failed^ 23 (4.0) 32 (6.1) <0.001 5 (2.4) 14 (8.5) 0.008
Default‡‡ 160 (27.8) 65 (12.3) <0.001 66 (31.1) 32 (19.5) 0.025
Transferred
out^^
2 (0.4) 12 (2.3) ** 0 4 (2.4) **
Data are number (%), unless otherwise indicated
¶
Treatment outcome definitions used are WHO definitions for the management of MDR-TB (Box 1). 17,18
*
Cured: Cure was defined as completion of treatment and >5 consecutive negative culture results in the final 12 months of treatment. A patient 
was still considered cured If only one positive culture was reported during this time, was clinically well, and this positive culture was followed by 
at least 3 consecutive negative cultures taken at least 30 days apart.
¥
Treatment completed: Treatment completion referred to completion of therapy but without bacteriologic documentation of cure.
**
Treatment success: Treatment success has been defined as the percentage of patients in whom the treatment outcome was either cured or 
completed. That is, “% successful = no. of patients cured + no. of patients completed treatment /Total no. initiated treatment × 100”.has been 
defined as the percentage of patients in whom the treatment outcome was either cured or completed. That is, “% successful = no. of patients cured 
+ no. of patients completed Rx/Total no. initiated Rx × 100.
†
Died: Death was defined as all-cause mortality during MDR-TB treatment.
^
Failed: Treatment failure was defined as having more than one positive culture in the final 12 months of therapy, or if any one of the final three 
cultures was positive, or if more than one drug in the treatment regimen was replaced, or if treatment was terminated due to adverse events or no 
clinical improvement.
‡‡
Default: Default was defined as an interruption in treatment for > 2 consecutive months for any reason.
^^
Transferred out: A patient with MDR-TB who was transferred to another reporting and recording unit a year after study-enrolment whose 
treatment outcome is unknown.
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